Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

54 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Intrinsic resistance and efficacy of immunotherapy in microsatellite instability-high colorectal cancer: A systematic review and meta-analysis.Biomolecules & biomedicine · 2023
   Pooled it
2. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review.International journal of molecular sciences · 2020
   Pooled it
3. Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma.Cancer research communications · 2026
   Article
4. Real-World 30-Day Mortality After the Last Dose of Immune Checkpoint Inhibitors: A Multicenter Retrospective Cohort Study in Turkey.Current oncology (Toronto, Ont.) · 2026
   Article
5. Exploring the Molecular and Genomic Landscape of the Dark Agouti Rat Mammary Adenocarcinoma: Preliminary Insights for Triple-Negative Breast Cancer Modeling.Journal of mammary gland biology and neoplasia · 2026
   Article
6. Tumor Microenvironment: Recent Advances in Immunotherapies of Pancreatic Cancer.Medicina (Kaunas, Lithuania) · 2025
   Review
7. ImmuProgML: machine learning-based dissection of cancer-immune dynamics during tumor progression to improve immunotherapy.Journal of translational medicine · 2025
   Article
8. Decoding the immune landscape in Ewing sarcoma pathogenesis: The role of tumor infiltrating immune cells and immune milieu.Journal of bone oncology · 2025
   Review
9. The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.Korean journal of clinical oncology · 2024
   Review
10. The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2024
    Article
11. Biomaterial-Based In Situ Cancer Vaccines.Advanced materials (Deerfield Beach, Fla.) · 2024
    Review
12. Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy.ACS omega · 2024
    Review
13. The Impact of Modern Dietary Practices on Cancer Risk and Progression: A Systematic Review.Cureus · 2023
    Review
14. Borrowing Concurrent Information from Non-Concurrent Control to Enhance Statistical Efficiency in Platform Trials.Current oncology (Toronto, Ont.) · 2023
    Article
15. Drug Delivery Systems for Localized Cancer Combination Therapy.ACS applied bio materials · 2023
    Review
16. T cell-dependent bispecific antibodies alter organ-specific endothelial cell-T cell interaction.EMBO reports · 2023
    Article
17. Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives.Frontiers in psychology · 2023
    Article
18. Synergizing liver systemic treatments with interventional oncology: friend or foe?The British journal of radiology · 2022
    Review
19. Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Article
20. Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort.BMC cancer · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract